Endonovo Therapeutics (OTCMKTS:ENDVD) and Spruce Biosciences (NASDAQ:SPRB) Head-To-Head Analysis

Endonovo Therapeutics (OTCMKTS:ENDVD) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Endonovo Therapeutics and Spruce Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Endonovo Therapeutics	-6,075.54%	N/A	-279.35%
Spruce Biosciences	N/A	-155.40%	-101.67%

Earnings and Valuation

This table compares Endonovo Therapeutics and Spruce Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Endonovo Therapeutics	$170,000.00	0.00	-$400,000.00	($10.00)	N/A
Spruce Biosciences	$4.91 million	30.24	-$38.97 million	($36.60)	-1.48

Endonovo Therapeutics has higher earnings, but lower revenue than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Endonovo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Endonovo Therapeutics has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.11, suggesting that its share price is 211% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Endonovo Therapeutics and Spruce Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Endonovo Therapeutics	0	0	0	0	0.00
Spruce Biosciences	1	2	7	0	2.60

Spruce Biosciences has a consensus target price of $163.00, indicating a potential upside of 201.85%. Given Spruce Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Endonovo Therapeutics.

Institutional & Insider Ownership

91.7% of Spruce Biosciences shares are held by institutional investors. 5.6% of Endonovo Therapeutics shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Spruce Biosciences beats Endonovo Therapeutics on 8 of the 13 factors compared between the two stocks.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.